SSIs are not designed for incremental improvements to the ‘standard of treatment’ – they are designed to re-invent, complement, and replace the standard.
Dr. Simon Sutcliffe, Chief Medical Officer, Qu Biologics
Supported by a committed group of investors.
Qu Biologics is a private, clinical-stage biotechnology company. Qu Biologics has raised USD$35M in equity funding from high net worth, family offices, and angel investors, and an additional USD$15M in non-dilutive funding.
Rather than blocking or stimulating a single receptor or pathway, SSI treatments are designed to restore the full depth and breadth of the body's normal immune response in a targeted organ. We believe this new approach has the potential to revolutionize the way cancer, chronic inflammatory diseases, and metabolic disease are treated and prevented. We are passionate and innovative and committed to achieve this goal and the full potential of SSIs.
Investment opportunity.
Qu Biologics is raising a USD$4M equity round to achieve transformation milestone data in our PERIOP-06 Phase 2 randomized controlled clinical study in patients with late-stage colon cancer undergoing resection of liver metastases (n=115) and a Phase 1/2 open-label study in CAR T-cell/SSI combination therapy in solid tumors (n=15). Please join us in transforming Medicine.
If you are interested in investment opportunities and learning more about our novel treatment approach and the innovative team behind it, contact CEO Dr. Hal Gunn at hal@qubiologics.com, or click on one of the four links, below, for additional information.
